Literature DB >> 21519175

[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].

Jae Yeon Kim1, Na Young Kim, Sung Jung Kim, Gwang Ho Baik, Gwang Ha Kim, Jung Mogg Kim, Ryoung Hee Nam, Hong Bin Kim, Dong Ho Lee, Hyun Chae Jung, In Sung Song.   

Abstract

BACKGROUND/AIMS: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea.
METHODS: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method.
RESULTS: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference.
CONCLUSIONS: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519175     DOI: 10.4166/kjg.2011.57.4.221

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  13 in total

1.  Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Authors:  Hyuk Soon Choi; Hoon Jai Chun; Sang Hoon Park; Bora Keum; Yeon Seok Seo; Yong Sik Kim; Yoon-Tae Jeen; Soon Ho Um; Hong Sik Lee; Chang Duck Kim; Ho Sang Ryu
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

2.  Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.

Authors:  Ju Yup Lee; Nayoung Kim; Min Soo Kim; Yoon Jin Choi; Jung Won Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Dig Dis Sci       Date:  2014-03-06       Impact factor: 3.199

Review 3.  Antibiotic treatment for Helicobacter pylori: Is the end coming?

Authors:  Su Young Kim; Duck Joo Choi; Jun-Won Chung
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

4.  Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea.

Authors:  Byoungrak An; Byung Soo Moon; Heejung Kim; Hyun Chul Lim; Yong Chan Lee; Gyusang Lee; Sa-Hyun Kim; Min Park; Jong Bae Kim
Journal:  Ann Lab Med       Date:  2013-10-17       Impact factor: 3.464

5.  Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?

Authors:  Eun Jeong Gong; Sung-Cheol Yun; Hwoon-Yong Jung; Hyun Lim; Kwi-Sook Choi; Ji Yong Ahn; Jeong Hoon Lee; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

6.  Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis.

Authors:  Beom Jin Kim; Hyun-Soo Kim; Hyun Joo Song; Il-Kwun Chung; Gwang Ha Kim; Byung-Wook Kim; Ki-Nam Shim; Seong Woo Jeon; Yun Jin Jung; Chang-Hun Yang; Ji Hyun Kim; Tae Ho Kim; Sang Gyun Kim; Woon Geon Shin; Sun Moon Kim; Sok Won Han; Jun Haeng Lee; Kyung Ho Kim; Sue K Park; Byung-Joo Park; Joongyub Lee; Jae G Kim
Journal:  J Korean Med Sci       Date:  2016-05-16       Impact factor: 2.153

7.  Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication.

Authors:  Ji Young Chang; Ki-Nam Shim; Chung Hyun Tae; Ko Eun Lee; Jihyun Lee; Kang Hoon Lee; Chang Mo Moon; Seong-Eun Kim; Hye-Kyung Jung; Sung-Ae Jung
Journal:  BMC Gastroenterol       Date:  2017-01-21       Impact factor: 3.067

8.  Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea.

Authors:  Ji Yoon Moon; Gwang Ha Kim; Hyun Seok You; Bong Eun Lee; Dong Yeop Ryu; Jae Hoon Cheong; Jung Im Jung; Jae Hoon Jeong; Chul Soo Song; Geun Am Song
Journal:  Gut Liver       Date:  2013-06-11       Impact factor: 4.519

9.  Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.

Authors:  Kyu-Hyun Yoon; Sung Woon Park; Sang Wook Lee; Beom Jin Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

10.  Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.

Authors:  Sung Eun Kim; Moo In Park; Seun Ja Park; Won Moon; Youn Jung Choi; Ji Hyun Cheon; Hye Jung Kwon; Ki Hwan Ku; Chang Hun Yoo; Jae Hyun Kim; Gyu Won Lee; Sung Eun Song
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.